BCL2 and cancer: Inhibiting the function of anti-apoptotic Bcl-2 proteins has become a validated approach for developing novel cancer therapies10,12,13, and recently resulted in the FDA approval of the selective Bcl-2 inhibitor, venetoclax (ABT-199)14.